Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: A randomized controlled trial

Human Reproduction

Volumn 30, Issue 2, 2015, Pages 432-440

  Kolibianakis, E M ^a   Venetis, C A ^a,b   Bosdou, J K ^a   Zepiridis, L ^a   Chatzimeletiou, K ^a   Makedos, A ^a   Masouridou, S ^a   Triantafillidis, S ^a   Mitsoli, A ^a   Tarlatzis, B C ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Corifollitropin alfa; Follitropin beta; In vitro fertilization; Poor ovarian response; Recombinant FSH

Indexed keywords

CHORIONIC GONADOTROPIN; CORIFOLLITROPIN ALFA; ESTRADIOL; FOLLITROPIN; GANIRELIX; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; FERTILITY PROMOTING AGENT; FOLLICLE STIMULATING HORMONE, HUMAN, WITH HCG C-TERMINAL PEPTIDE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; CUMULUS OOCYTE COMPLEX; DISEASE DURATION; EMBRYO TRANSFER; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTENTION TO TREAT ANALYSIS; INTRACYTOPLASMIC SPERM INJECTION; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OOCYTE; OOCYTE MATURATION; OOCYTE RETRIEVAL; OPEN STUDY; OUTCOME ASSESSMENT; OVARIAN STIMULATION; PREGNANCY OUTCOME; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ADVERSE EFFECTS; BIRTH RATE; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; DRUG RESISTANCE; ECTOGENESIS; EPIDEMIOLOGY; FAMILY SIZE; FEASIBILITY STUDY; GREECE; INFERTILITY, FEMALE; MALE; MALE INFERTILITY; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; BIRTH RATE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG RESISTANCE; ECTOGENESIS; FAMILY CHARACTERISTICS; FEASIBILITY STUDIES; FEMALE; FERTILITY AGENTS, FEMALE; FOLLICLE STIMULATING HORMONE, HUMAN; GREECE; HUMANS; INFERTILITY, FEMALE; INFERTILITY, MALE; INJECTIONS, SUBCUTANEOUS; MALE; OOCYTE RETRIEVAL; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RECOMBINANT PROTEINS; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 84930691674     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deu301     Document Type: Article

References (30)

1. Aletebi F. Comparing gonadotrophin-releasing hormone agonists or gonadotrophin-releasing hormone antagonists in poor responders in IVF. Fertil Soc J 2007;12:2-3.
2. Bosdou JK, Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Zepiridis L, Tarlatzis BC. The use of androgens or androgen-modulating agents in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update 2012;18:127-145.
3. Corifollitropin Alfa Dose-finding Study Group.Arandomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Hum Reprod 2008; 23:2484-2492.
4. de Greef R, Zandvliet AS, de Haan AF, Ijzerman-Boon PC, Marintcheva-Petrova M, Mannaerts BM. Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clin Pharmacol Ther 2010;88:79-87.
5. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC, Investigators E. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009;24:3063-3072.
6. Fauser BC, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BM, Engage I. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reprod Biomed Online 2010;21:593-601.
7. Ferraretti AP, Gianaroli L. The Bologna criteria for the definition of poor ovarian responders: is there a need for revision? Hum Reprod 2014; 29:1842-1845.
8. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L;ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011;26:1616-1624.
9. Frydman R. Poor responders: still a problem. Fertil Steril 2011;96:1057.
10. Hintze J. PASS 11. NCSS, LLC. Kaysville. Utah, USA. 2011. www.ncss.com.
11. Huirne JA, Hugues JN, Pirard C, Fischl F, Sage JC, Pouly JL, Obruca A, Braat DM, van Loenen AC, Lambalk CB. Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study. Hum Reprod 2006;21:1408-1415.
12. Kolibianakis EM, Venetis CA, Diedrich K, Tarlatzis BC, Griesinger G. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update 2009;15:613-622.
13. Kolibianakis EM, Venetis CA, Tarlatzis BC. DHEA administration in poor responders. Hum Reprod 2011;26:730-731; author reply 731.
14. Kolibianakis EM, Venetis CA, Bontis J, Tarlatzis BC. Significantly lower pregnancy rates in the presence of progesterone elevation in patients treated with GnRH antagonists and gonadotrophins: a systematic review and meta-analysis. Curr Pharm Biotechnol 2012;13:464-470.
15. Kyrou D, Kolibianakis EM, Venetis CA, Papanikolaou EG, Bontis J, Tarlatzis BC. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril 2009;91:749-766.
16. Lefebvre J, Antaki R, Dean N, Sylvestre C, Bissonnette F, Kadoch IJ, Benoit J, Ménard S, Monceau E, Lapensée L. 450 IU vs. 600 IU of gonadotropins for controlled ovarian stimulation in poor responders: a randomized controlled trial. Hum Reprod 2014;29:I14.
17. Lehert P, Kolibianakis EM, Venetis CA, Schertz J, Saunders H, Arriagada P, Copt S, Tarlatzis B. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod Biol Endocrinol 2014;12:17.
18. Mannaerts BM, Rombout F, Out HJ, Coelingh Bennink H. Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy. Hum Reprod Update 1996; 2:153-161.
19. Moon SY, Choi YS,Ku SY, KimSH, Choi YM,Kang IS, KimCH. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology. J Obstet Gynaecol Res 2007;33:305-315.
20. Papathanasiou A. Implementing the ESHRE 'poor responder' criteria in research studies: methodological implications. Hum Reprod 2014; 29:1835-1838.
21. Polyzos NP, De Vos M, Corona R, Vloeberghs V, Ortega-Hrepich C, Stoop D, Tournaye H. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study. Hum Reprod 2013a;28:1254-1260.
22. Polyzos NP, Devos M, Humaidan P, Stoop D, Ortega-Hrepich C, Devroey P, Tournaye H. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study. Fertil Steril 2013b;99:422-426.
23. Templeton A, Morris JK. Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. N Engl J Med 1998; 339:573-577.
24. Venetis CA. The Bologna criteria for poor ovarian response: the good, the bad and the way forward. Hum Reprod 2014;29:1839-1841.
25. Venetis CA, Kolibianakis EM, Papanikolaou E, Bontis J, Devroey P, Tarlatzis BC. Is progesterone elevation on the day of human chorionic gonadotrophin administration associated with the probability of pregnancy in in vitro fertilization? A systematic review and meta-analysis. Hum Reprod Update 2007;13:343-355.
26. Venetis CA, Kolibianakis EM, Tarlatzi TB, Tarlatzis BC. Evidence-based management of poor ovarian response. Ann N Y Acad Sci 2010; 1205:199-206.
27. Venetis CA, Kolibianakis EM, Bosdou JK, Tarlatzis BC. Progesterone elevation and probability of pregnancy after IVF: a systematic reviewandmeta-analysis of over 60 000 cycles. Hum Reprod Update 2013;19:433-457.
28. Weitzman VN, Engmann L, Di Luigi A, Maier D, Nulsen J, Benadiva C. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes. Fertil Steril 2009;92:226-230.
29. Younis JS. The Bologna criteria for poor ovarian response; has the job been accomplished? Hum Reprod 2012;27:1874-1875.
30. Ziebe S, Petersen K, Lindenberg S, Andersen AG, Gabrielsen A, Andersen AN. Embryo morphology or cleavage stage: how to select the best embryos for transfer after in-vitro fertilization. Hum Reprod 1997; 12:1545-1549.